Aliases for AKR1B1 Gene
External Ids for AKR1B1 Gene
Previous HGNC Symbols for AKR1B1 Gene
Previous GeneCards Identifiers for AKR1B1 Gene
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This member catalyzes the reduction of a number of aldehydes, including the aldehyde form of glucose, and is thereby implicated in the development of diabetic complications by catalyzing the reduction of glucose to sorbitol. Multiple pseudogenes have been identified for this gene. The nomenclature system used by the HUGO Gene Nomenclature Committee to define human aldo-keto reductase family members is known to differ from that used by the Mouse Genome Informatics database. [provided by RefSeq, Feb 2009]
GeneCards Summary for AKR1B1 Gene
AKR1B1 (Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase)) is a Protein Coding gene. Diseases associated with AKR1B1 include diabetic neuropathy and diabetic autonomic neuropathy. Among its related pathways are Pathways in cancer and Akt Signaling. GO annotations related to this gene include electron carrier activity and alditol:NADP+ 1-oxidoreductase activity. An important paralog of this gene is AKR1C2.
UniProtKB/Swiss-Prot for AKR1B1 Gene
Catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols with a broad range of catalytic efficiencies
Aldose reductase (also known as aldehyde reductase) catalyzes the reduction of a wide variety of hydrophobic and hydrophilic carbonyl-containing compounds to their corresponding alcohols. This enzyme is cytosolic, exists as a monomer and requires NADPH as a co-factor. Aldose reductase catalyzes the rate-limiting step of the polyol pathway (the conversion of glucose to sorbitol), a pathway that is overactive in diabetes mellitus and the cause of diabetic complications. Aldose reductase is expressed in most mammalian tissues and is found at high concentrations in the seminal vesicles, lens, retina, renal medulla and sciatic nerve. Currently there is much interest in the development of pharmalogical inhibitors targeting this enzyme as a method of preventing the complications associated with chronic hyperglycemia.